The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Open accessAbstract
Background and Purpose: Cannabidiol has been reported to act as an antagonist at cannabinoid CB 1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB 1 receptors. Experimental Approach: Internalization of CB 1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB 1 receptors and in the ST Hdh Q7/Q7 cell model of striatal neurons endogenously expressing CB 1 receptors. Cells were treated with 2‐arachidonylglycerol or Δ 9 ‐tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol. Key Results: Cannabidiol reduced the efficacy and potency of 2‐arachidonylglycerol and Δ 9 ‐tetrahydrocannabinol on PLCβ3‐ and ERK1/2‐dependent signalling in cells heterologously (HEK 293A) or endogenously (ST Hdh Q7/Q7 ) expressing CB 1 receptors. By reducing arrestin2 recruitment to CB 1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB 1 receptor. Conclusions and Implications: Cannabidiol behaved as a non‐competitive negative allosteric modulator of CB 1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB 1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB 1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cannabidiol (CBD; Epidolex®) acts as a negative allosteric modulator at CB1 receptors [7] and also acts at several other receptors, such as CB2 receptors, serotonin 1A receptors, opioid receptors and several ligand-gated ion channels [8]”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [7]
In the citing paper
“CBD has been termed a negative allosteric modulator at CB1R (Laprairie et al., 2015)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Laprairie et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 934
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 845
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763
Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells
Trettel, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2799 · Cited by 614
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 561
McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 552
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L., Easson, M., Goodwin, R. R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 449
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors
Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 379
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 326
James, J. R., Oliveira, M. I., Carmo, A. M., Iaboni, A., & Davis, S. J. (2006) · Nature Methods · doi:10.1038/nmeth978 · Cited by 320
Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor
Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.2794 · Cited by 320
Allosteric modulation of G protein-coupled receptors: A pharmacological perspective
Keov, P., Sexton, P. M., & Christopoulos, A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.010 · Cited by 265
Anti-inflammatory lipoxin A 4 is an endogenous allosteric enhancer of CB 1 cannabinoid receptor
Pamplona, F. A., Ferreira, J., de Lima, O. M., Duarte, F. S., Bento, A. F., Forner, S., Villarinho, J. G., Bellocchio, L., Wotjak, C. T., Lerner, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202906109 · Cited by 178
Horswill, J. G., Bali, U., Shaban, S. N., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & In, P. W. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707347 · Cited by 176
Pertwee, R. G., Ross, R. A., Craib, S. J., & Thomas, A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02624-9 · Cited by 156
Ahn, K. H., Mahmoud, M. M., & Kendall, D. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316463 · Cited by 149
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Dupré, D. J., & Denovan‐Wright, E. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557025 · Cited by 141
Self-citationAhn, K. H., Mahmoud, M. M., Shim, J., & Kendall, D. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438804 · Cited by 136
Hayakawa, K., Mishima, K., Hazekawa, M., Sano, K., Irie, K., Orito, K., Egawa, T., Kitamura, Y., Uchida, N., Nishimura, R., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.090 · Cited by 134
CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity
Baillie, G. L., Horswill, J. G., Anavi‐Goffer, S., Reggio, P. H., Bolognini, D., Abood, M. E., McAllister, S. D., Strange, P. G., Stephens, G. J., Pertwee, R. G., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080879 · Cited by 113
Cawston, E. E., Redmond, W. J., Breen, C. M., Grimsey, N. L., Connor, M. A., & Glass, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12329 · Cited by 110
Allosterism and cannabinoid CB1 receptors: the shape of things to come
ROSS, R. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.006 · Cited by 93
Canals, M., & Milligan, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710300200 · Cited by 86
Physical and functional interaction between CB1cannabinoid receptors and β2‐adrenoceptors
Hudson, B. D., Hébert, T. E., & Kelly, M. E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00681.x · Cited by 83
Self-citationSmith, N. J., Ward, R. J., Stoddart, L. A., Hudson, B. D., Kostenis, E., Ulven, T., Morris, J. C., Tränkle, C., Tikhonova, I. G., Adams, D. R., et al. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070789 · Cited by 79
Lee, J.-M., Ivanova, E. V., Seong, I. S., Cashorali, T., Kohane, I., Gusella, J. F., & MacDonald, M. E. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030135 · Cited by 71
Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands
Hudson, B. D., Christiansen, E., Murdoch, H., Jenkins, L., Hansen, A. H., Madsen, O., Ulven, T., & Milligan, G. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093294 · Cited by 71
In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569
Gamage, T. F., Ignatowska-Jankowska, B. M., Wiley, J. L., Abdelrahman, M., Trembleau, L., Greig, I. R., Thakur, G. A., Tichkule, R. B., Poklis, J. L., Ross, R. A., et al. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000027 · Cited by 63
Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor
Piscitelli, F., Ligresti, A., Regina, G. L., Coluccia, A., Morera, L., Allarà, M., Novellino, E., Marzo, V. D., & Silvestri, R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201485c · Cited by 63
Fay, J. F., & Farrens, D. (2013) · Biochemistry · doi:10.1021/bi400842k · Cited by 47
Ferreira, S. G., Teixeira, F. M., Garção, P., Agostinho, P. M., Ledent, C. A., Cortes, L., Mackie, K., & Köfalvi, A. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.009 · Cited by 43
Laprairie, R. B., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.006 · Cited by 43
Self-citationWang, X., Horswill, J. G., Whalley, B. J., & Stephens, G. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068197 · Cited by 39
Bagher, A. M., Laprairie, R. B., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.002 · Cited by 37
Self-citationInteractions of cannabidiol with endocannabinoid signalling in hippocampal tissue
Ryan, D., Drysdale, A. J., Pertwee, R. G., & Platt, B. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05448.x · Cited by 35
Wiley, J. L., Breivogel, C. S., Mahadevan, A., Pertwee, R. G., Cascio, M. G., Bolognini, D., Huffman, J. W., Walentiny, D. M., Vann, R. E., Razdan, R. K., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.085 · Cited by 32
Higuchi, S., Irie, K., Mishima, S., Araki, M., Ohji, M., Shirakawa, A., Akitake, Y., Matsuyama, K., Mishima, K., Mishima, K., et al. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09326sc · Cited by 23
The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans
Anderson, R. L., Randall, M. D., & Chan, S. L. F. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.034 · Cited by 18
Laprairie, R. B., Warford, J. R., Hutchings, S., Robertson, G. S., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.12.008 · Cited by 18
Self-citationStructural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice
Wiley, J. L., Marusich, J. A., Zhang, Y., Fulp, A. B., Maitra, R., Thomas, B. F., & Mahadevan, A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.08.019 · Cited by 13
Cited by
Sorted by citations
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,448
Phytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 889
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Metadata
- Authors
- Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M.
- Affiliations
- Dalhousie University (CA)
- Corresponding author
- Denovan‐Wright, E M
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2015-10
- Volume
- 172
- Issue
- 20
- Pages
- 4790-4805
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC4621983
- OpenAlex
- W1945751328
- Cited by
- 1,039
- References
- 47
- Citations by year
- 2026: 92 · 2025: 107 · 2024: 107 · 2023: 107 · 2022: 133 · 2021: 150 · 2020: 125 · 2019: 89 · 2018: 54 · 2017: 49 · 2016: 19 · 2015: 6
- FWCI
- 30.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (ROP-97185, MOP-97768)
- Killam Trusts
- Nova Scotia Health Research Foundation
- King Abdulaziz University of Saudi Arabia
- Huntington Society of Canada
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabidiol, CB1 receptor, negative allosteric modulation, receptor internalization, ERK1/2 phosphorylation, 2-arachidonoylglycerol, delta-9-tetrahydrocannabinol, allosteric modulators, non-competitive antagonism
- MeSH terms
- Animals, Cannabidiol, Cell Line, Humans, Arrestins, MAP Kinase Signaling System, Receptor, Cannabinoid, CB1, Mice, Phospholipase C beta, HEK293 Cells, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
